Gonca Bektas, Edibe Pembegul Yildiz, Burak Tatli, Nur Aydinli, Mine Caliskan and Meral Ozmen
Background: Guillain-Barre syndrome (GBS) is an acute immune-mediated demyelinating polyneuropathy, and it has been suggested that immune-mediated mechanism underlying the pathogenesis of GBS was triggered by infectious agents, vaccination, head trauma, operation, and malignancy. Risperidone, one of the secondgeneration antipsychotic drugs, tends to alter cytokine levels that could partly be attributed to GBS occurrence.
Findings: We herein present a 7 year-old-girl who developed GBS under risperidone treatment. The possibility of occurrence of GBS triggered by risperidone was analyzed using causality assessment scales of Naranjo and World Health Organization Collaborating Centre for International Drug Monitoring, the Uppsala Monitoring Centre (WHO–UMC). The results indicated that risperidone was a probable cause of GBS.
Conclusion: Patients with newly-emerging neurologic symptoms under risperidone should undergo detailed neurologic examination, and if necessary neurophysiologic assessment.
English 
Spanish 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi